Celastrol Blocks Neuronal Cell Death and Extends Life in Transgenic Mouse Model of Amyotrophic Lateral Sclerosis

There is substantial evidence that both inflammation and oxidative damage contribute to the pathogenesis of motor neuron degeneration in the G93A SOD1 transgenic mouse model of amyotrophic lateral sclerosis (ALS). Celastrol is a natural product from Southern China, which exerts potent anti-inflammatory and antioxidative effects. It also acts potently to increase expression of heat shock proteins including HSP70. We administered it in the diet to G93A SOD1 mice starting at 30 days of age. Celastrol treatment significantly improved weight loss, motor performance and delayed the onset of ALS. Survival of celastrol-treated G93A mice increased by 9.4% and 13% for 2 mg/kg/day and 8 mg/kg/day doses, respectively. Cell counts of lumbar spinal cord neurons confirmed a protective effect, i.e. 30% increase in neuronal number in the lumbar spinal cords of celastrol-treated animals. Celastrol treatment reduced TNF-α, iNOS, CD40, and GFAP immunoreactivity in the lumbar spinal cord sections of celastrol-treated G93A mice compared to untreated G93A mice. TNF-α immunoreactivity co-localized with SMI-32 (neuronal marker) and GFAP (astrocyte marker). HSP70 immunoreactivity was increased in lumbar spinal cord neurons of celastrol-treated G93A mice. Celastrol has been widely used in treating inflammatory diseases in man, and is well tolerated; therefore, it may be a promising therapeutic candidate for the treatment of human ALS.

[1]  S. Hsu,et al.  Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. , 1981, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[2]  D. Green,et al.  The Pathophysiology of Mitochondrial Cell Death , 2004, Science.

[3]  M. Beal,et al.  Additive neuroprotective effects of creatine and cyclooxygenase 2 inhibitors in a transgenic mouse model of amyotrophic lateral sclerosis , 2003, Journal of neurochemistry.

[4]  A. Tiwari,et al.  Inhibition of Chaperone Activity Is a Shared Property of Several Cu,Zn-Superoxide Dismutase Mutants That Cause Amyotrophic Lateral Sclerosis* , 2005, Journal of Biological Chemistry.

[5]  B. Hwang,et al.  Antiinflammatory constituents of Celastrus orbiculatus inhibit the NF-kappaB activation and NO production. , 2002, Journal of natural products.

[6]  H. Beere.  `The stress of dying': the role of heat shock proteins in the regulation of apoptosis , 2004, Journal of Cell Science.

[7]  Josef M. Penninger,et al.  Heat-shock protein 70 antagonizes apoptosis-inducing factor , 2001, Nature Cell Biology.

[8]  Robert H. Brown,et al.  Evidence of Increased Oxidative Damage in Both Sporadic and Familial Amyotrophic Lateral Sclerosis , 1997, Journal of neurochemistry.

[9]  M. Gurney,et al.  Relationship of microglial and astrocytic activation to disease onset and progression in a transgenic model of familial ALS. , 1998, Glia.

[10]  M. Gurney,et al.  Relationship of microglial and astrocytic activation to disease onset and progression in a transgenic model of familial ALS , 1998 .

[11]  T. Conrad,et al.  A clinical trial of creatine in ALS , 2004, Neurology.

[12]  A. Allison,et al.  Celastrol, a potent antioxidant and anti-inflammatory drug, as a possible treatment for Alzheimer's disease , 2001, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[13]  A. Allison,et al.  Inhibitory effect of di-catechol rooperol on VCAM-1 and iNOS expression in cytokine-stimulated endothelium. , 1996, Life sciences.

[14]  M. Beal,et al.  Integrative role of cPLA2 with COX‐2 and the effect of non‐steriodal anti‐inflammatory drugs in a transgenic mouse model of amyotrophic lateral sclerosis , 2005, Journal of neurochemistry.

[15]  A. Zilberstein,et al.  Novel cytokine release inhibitors. Part III: Truncated analogs of tripterine. , 1998, Bioorganic & medicinal chemistry letters.

[16]  J. Elliott.  Cytokine upregulation in a murine model of familial amyotrophic lateral sclerosis. , 2001, Brain research. Molecular brain research.

[17]  M. Beal,et al.  Peroxisome proliferator-activated receptor-gamma agonist extends survival in transgenic mouse model of amyotrophic lateral sclerosis , 2005, Experimental Neurology.

[18]  Minh N. H. Nguyen,et al.  Induction of proinflammatory molecules in mice with amyotrophic lateral sclerosis: No requirement for proapoptotic interleukin‐1β in neurodegeneration , 2001, Annals of neurology.

[19]  S. Przedborski,et al.  Inducible Nitric Oxide Synthase Up‐Regulation in a Transgenic Mouse Model of Familial Amyotrophic Lateral Sclerosis , 1999, Journal of neurochemistry.

[20]  G. Rosoklija,et al.  Increased expression of the pro‐inflammatory enzyme cyclooxygenase‐2 in amyotrophic lateral sclerosis , 2001, Annals of neurology.

[21]  M. Strong,et al.  High Threshold for Induction of the Stress Response in Motor Neurons Is Associated with Failure to Activate HSF1 , 2003, The Journal of Neuroscience.

[22]  K. Kogure,et al.  Structural basis of potent antiperoxidation activity of the triterpene celastrol in mitochondria: effect of negative membrane surface charge on lipid peroxidation. , 1994, Free radical biology & medicine.

[23]  T. Siddique,et al.  Molecular genetic basis of familial ALS , 1996, Neurology.

[24]  J. Haines,et al.  Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis , 1993, Nature.

[25]  M. Gurney,et al.  Increased 3‐nitrotyrosine and oxidative damage in mice with a human copper/zinc superoxide dismutase mutation , 1997, Annals of neurology.

[26]  S. Westerheide,et al.  Celastrols as Inducers of the Heat Shock Response and Cytoprotection*[boxs] , 2004, Journal of Biological Chemistry.

[27]  W. Robberecht,et al.  Upregulation of HSP27 in a Transgenic Model of ALS , 2002, Journal of neuropathology and experimental neurology.

[28]  Robert H. Brown,et al.  Increased 3‐nitrotyrosine in both sporadic and familial amyotrophic lateral sclerosis , 1997, Annals of neurology.

[29]  H. Terada,et al.  The triterpene celastrol as a very potent inhibitor of lipid peroxidation in mitochondria. , 1990, Biochemical and biophysical research communications.

[30]  Wendy Bruening,et al.  Up‐Regulation of Protein Chaperones Preserves Viability of Cells Expressing Toxic Cu/Zn‐Superoxide Dismutase Mutants Associated with Amyotrophic Lateral Sclerosis , 1999, Journal of neurochemistry.

[31]  K. Nakayama,et al.  CHIP promotes proteasomal degradation of familial ALS‐linked mutant SOD1 by ubiquitinating Hsp/Hsc70 , 2004, Journal of neurochemistry.

[32]  G. Sobue,et al.  Differential expression of inflammation‐ and apoptosis‐related genes in spinal cords of a mutant SOD1 transgenic mouse 
model of familial amyotrophic lateral sclerosis , 2002, Journal of neurochemistry.

[33]  D. Borchelt,et al.  ALS-Linked SOD1 Mutant G85R Mediates Damage to Astrocytes and Promotes Rapidly Progressive Disease with SOD1-Containing Inclusions , 1997, Neuron.

[34]  M. Beal,et al.  Celastrol protects against MPTP‐ and 3‐nitropropionic acid‐induced neurotoxicity , 2005, Journal of neurochemistry.

[35]  S. Minotti,et al.  Mutant Cu/Zn-Superoxide Dismutase Proteins Have Altered Solubility and Interact with Heat Shock/Stress Proteins in Models of Amyotrophic Lateral Sclerosis* , 2001, The Journal of Biological Chemistry.

[36]  Hiroshi Nishimune,et al.  Motoneuron Death Triggered by a Specific Pathway Downstream of Fas Potentiation by ALS-Linked SOD1 Mutations , 2002, Neuron.

[37]  M. Beal,et al.  Elevated “Hydroxyl Radical” Generation In Vivo in an Animal Model of Amyotrophic Lateral Sclerosis , 1998, Journal of neurochemistry.

[38]  Geoffrey Burnstock,et al.  Treatment with arimoclomol, a coinducer of heat shock proteins, delays disease progression in ALS mice , 2004, Nature Medicine.

[39]  M. Beal,et al.  Iron porphyrin treatment extends survival in a transgenic animal model of amyotrophic lateral sclerosis , 2003, Journal of neurochemistry.

[40]  D. Troost,et al.  Decrease of Hsp25 protein expression precedes degeneration of motoneurons in ALS‐SOD1 mice , 2004, The European journal of neuroscience.

[41]  F. Huang,et al.  Novel cytokine release inhibitors. Part II: Steroids. , 1998, Bioorganic & medicinal chemistry letters.

[42]  Scott Ferrell,et al.  Message and protein-level elevation of tumor necrosis factor α (TNFα) and TNFα-modulating cytokines in spinal cords of the G93A-SOD1 mouse model for amyotrophic lateral sclerosis , 2003, Neurobiology of Disease.

[43]  A. Zilberstein,et al.  Novel cytokine release inhibitors. Part I: Triterpenes. , 1998, Bioorganic & medicinal chemistry letters.

[44]  Scott Ferrell,et al.  Message and protein-level elevation of tumor necrosis factor alpha (TNF alpha) and TNF alpha-modulating cytokines in spinal cords of the G93A-SOD1 mouse model for amyotrophic lateral sclerosis. , 2003, Neurobiology of disease.

[45]  J. Morrison,et al.  Transgenic mice expressing an altered murine superoxide dismutase gene provide an animal model of amyotrophic lateral sclerosis. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[46]  X. Tao,et al.  A prospective, controlled, double-blind, cross-over study of tripterygium wilfodii hook F in treatment of rheumatoid arthritis. , 1989, Chinese medical journal.

[47]  L. Deecke,et al.  Increased levels of the pro-inflammatory prostaglandin PGE2 in CSF from ALS patients , 2002, Neurology.

[48]  M. Gurney,et al.  Protein Oxidative Damage in a Transgenic Mouse Model of Familial Amyotrophic Lateral Sclerosis , 1998, Journal of neurochemistry.

[49]  Robert G. Miller,et al.  ALS trial design: expectation and reality , 2004, Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases.

[50]  M. Gurney,et al.  Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation. , 1994, Science.

[51]  P. Stieg,et al.  Functional role of caspase-1 and caspase-3 in an ALS transgenic mouse model. , 2000, Science.

[52]  D. Borchelt,et al.  An adverse property of a familial ALS-linked SOD1 mutation causes motor neuron disease characterized by vacuolar degeneration of mitochondria , 1995, Neuron.

[53]  T. O’Halloran,et al.  Amyotrophic Lateral Sclerosis Mutations Have the Greatest Destabilizing Effect on the Apo- and Reduced Form of SOD1, Leading to Unfolding and Oxidative Aggregation* , 2005, Journal of Biological Chemistry.